13F
中

SPRO SPERO THERAPEUTICS INC

2026Q1 · CUSIP 84833T103 · Sector: Healthcare & Biotech

Neutral · No signal
Holders
49
Δ holders QoQ
-7
Breadth percentile
Top 82%
Whale holders
24
Δ whales
-1
Inst. holding value
$48M
New positions
8
Closed positions
15
Price momentum (1Q)
—
Put / Call
3/2

Breadth history (34 quarters)

2018Q1: Δ-2 · h=35 2018Q2: Δ+9 · h=44 2018Q3: Δ+10 · h=54 2018Q4: Δ-2 · h=52 2019Q1: Δ+4 · h=56 2019Q2: Δ+5 · h=61 2019Q3: Δ+0 · h=61 2019Q4: Δ+2 · h=63 2020Q1: Δ-2 · h=61 2020Q2: Δ+18 · h=79 2020Q3: Δ-2 · h=77 2020Q4: Δ+11 · h=88 2021Q1: Δ+6 · h=94 2021Q2: Δ-7 · h=87 2021Q3: Δ-1 · h=86 2021Q4: Δ-3 · h=83 2022Q1: Δ+15 · h=98 2022Q2: Δ-18 · h=80 2022Q3: Δ-10 · h=70 2022Q4: Δ-9 · h=61 2023Q1: Δ-12 · h=49 2023Q2: Δ+8 · h=57 2023Q3: Δ-2 · h=55 2023Q4: Δ-4 · h=51 2024Q1: Δ+4 · h=55 2024Q2: Δ-6 · h=49 2024Q3: Δ-2 · h=47 2024Q4: Δ+4 · h=51 2025Q1: Δ-11 · h=40 2025Q2: Δ+4 · h=44 2025Q3: Δ+3 · h=47 2025Q4: Δ+9 · h=56 2026Q1: Δ-7 · h=49 2018Q1: holders=35 2018Q2: holders=44 2018Q3: holders=54 2018Q4: holders=52 2019Q1: holders=56 2019Q2: holders=61 2019Q3: holders=61 2019Q4: holders=63 2020Q1: holders=61 2020Q2: holders=79 2020Q3: holders=77 2020Q4: holders=88 2021Q1: holders=94 2021Q2: holders=87 2021Q3: holders=86 2021Q4: holders=83 2022Q1: holders=98 2022Q2: holders=80 2022Q3: holders=70 2022Q4: holders=61 2023Q1: holders=49 2023Q2: holders=57 2023Q3: holders=55 2023Q4: holders=51 2024Q1: holders=55 2024Q2: holders=49 2024Q3: holders=47 2024Q4: holders=51 2025Q1: holders=40 2025Q2: holders=44 2025Q3: holders=47 2025Q4: holders=56 2026Q1: holders=49 -18 -9 +0 +9 +18 3167103 18Q119Q120Q121Q122Q123Q124Q125Q126Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 2 lit events

Period Percentile Next-1Q return Next-2Q return
2022Q1 Top 13% -35.2% +13.9%
2020Q2 Top 19% +11.4% +65.2%

Options Sentiment

Put holders
3
QoQ: +1
Call holders
2
QoQ: +2

See methodology →

Fundamentals

PE (TTM)
6.5
EPS (TTM)
$0.27
EPS YoY
—
Revenue (TTM)
$0.1B
Revenue YoY
+37.2%
Quarterly Revenue & EPS (4Y)
2022-06-30: $2M 2022-09-30: $2M 2022-12-31: $47M 2023-03-31: $2M 2023-06-30: $3M 2023-09-30: $25M 2023-12-31: $74M 2024-03-31: $9M 2024-06-30: $10M 2024-09-30: $13M 2024-12-31: $15M 2025-03-31: $6M 2025-06-30: $14M 2025-09-30: $5M 2025-12-31: $41M 2026-03-31: $0M 2022-06-30: EPS -0.87 2022-09-30: EPS -0.33 2022-12-31: EPS 0.98 2023-03-31: EPS -0.25 2023-06-30: EPS -0.23 2023-09-30: EPS -0.06 2023-12-31: EPS 0.97 2024-03-31: EPS -0.24 2024-06-30: EPS -0.33 2024-09-30: EPS -0.32 2024-12-31: EPS -0.38 2025-03-31: EPS -0.25 2025-06-30: EPS -0.03 2025-09-30: EPS -0.13 2025-12-31: EPS 0.56 2026-03-31: EPS -0.13 0M 37M 74M $M -0.96 0.06 1.08 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
4Y median 8 2023-06-30: PE 7.72023-09-30: PE 2.62023-12-31: PE 3.62024-03-31: PE 3.62024-06-30: PE 3.52024-09-30: PE 14.72025-12-31: PE 15.92026-03-31: PE 10.3 2 10 17 20222023202420252026

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)